Search

Phage Futures Congress 2020 is happening Feb 5-6, 2020 in Washington, DC. Early bird pricing ends Dec 6. Use discount code 'PHAGEDIRECTORY' for an extra 10% off! Hope to see you there!

Several new phage therapy reviews are out: one on the pharmacological limitations of phage therapy by Anders Nilsson, one on promises and pitfalls of in vivo evolution to improve phage therapy by James Bull and colleagues, and one on explor

Phages were successfully used to treat a 41-year old's cardiac infection, which involved a cardiac implantable electronic device and aortic graft, at the German Heart Center Berlin in Berlin, Germany.

Congratulations to Dr. Minmin Yen, CEO of PhagePro, a company developing a phage cocktail as a household cholera prophylactic — she just won $10,000 in the 2019 TropMed pitch competition hosted by the American Society for Tropical Medicine

Congratulations to Dr. Minmin Yen, CEO of PhagePro, a company developing a phage cocktail as a household cholera prophylactic — she just won $10,000 in the 2019 TropMed pitch competition hosted by the American Society for Tropical Medicine

Phages were successfully used to treat a 41-year old's cardiac infection, which involved a cardiac implantable electronic device and aortic graft, at the German Heart Center Berlin in Berlin, Germany.

Phage Futures Congress 2020 is happening Feb 5-6, 2020 in Washington, DC. Early bird pricing ends Dec 6. Use discount code 'PHAGEDIRECTORY' for an extra 10% off! Hope to see you there!

Several new phage therapy reviews are out: one on the pharmacological limitations of phage therapy by Anders Nilsson, one on promises and pitfalls of in vivo evolution to improve phage therapy by James Bull and colleagues, and one on explor

In collaboration with researchers at Brunel University London, a new UK synthetic biology company called CC Bio is developing phage lysins to target bacterial vaginosis caused by Gardnerella vaginalis. They've just received £250,000 in fund

This project is aimed at evaluating the use of bacteriophage to treat Staphyloccocus aureus colonization and/or disease in order to better combat multi-antibiotic-resistant bacterial pathogens. A major goal of this project is to establish a

Felix Biotechnology is a new phage company using phages to target antibiotic resistant bacteria based on their mechanism of antibiotic resistance (working with Yale University). They just won this year's Falling Walls Venture competition in

In collaboration with researchers at Brunel University London, a new UK synthetic biology company called CC Bio is developing phage lysins to target bacterial vaginosis caused by Gardnerella vaginalis. They've just received £250,000 in fund

This project is aimed at evaluating the use of bacteriophage to treat Staphyloccocus aureus colonization and/or disease in order to better combat multi-antibiotic-resistant bacterial pathogens. A major goal of this project is to establish a

Felix Biotechnology is a new phage company using phages to target antibiotic resistant bacteria based on their mechanism of antibiotic resistance (working with Yale University). They just won this year's Falling Walls Venture competition in

Yi Duan (UCSD) and colleagues have published an incredibly exciting paper showing that cytotoxin-secreting Enterococcus faecalis in the mouse gut is a cause of alcohol-induced liver disease in mice. Most excitingly, they used phages to targ

Shelley Gibson (Baylor College of Medicine) and colleagues have published a paper describing the generation of phage libraries against three pathogens: E. coli, P. aeruginosa and Enterobacter cloacae. They've characterized the phages system

Diane Shader Smith wrote a beautiful article commemorating the two-year anniversary of her daughter Mallory’s passing. Mallory passed away due to drug-resistant Burkholderia and cystic fibrosis. Diane remarks that Mallory's legacy lives on

BiomX just presented preclinical data on its development of a phage cocktail active against Klebsiella pneumoniae strains correlated with primary sclerosing cholangitis (PSC) severity. PSC is a liver disease with no FDA-approved treatment t

The Open Health Systems Colloquium and the International Bacteriophage Research Consortium will be hosting a lecture and panel discussion on "Charting a Path Toward Bacteriophage Therapy" on Nov. 19 from 6-8:30 PM at the India International

BiomX just presented preclinical data on its development of a phage cocktail active against Klebsiella pneumoniae strains correlated with primary sclerosing cholangitis (PSC) severity. PSC is a liver disease with no FDA-approved treatment t